Trial Profile
Upfront Riociguat and Ambrisentan Combination Therapy for Pulmonary Arterial Hypertension: A Safety and Efficacy Pilot Study
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 08 Mar 2022
Price :
$35
*
At a glance
- Drugs Ambrisentan (Primary) ; Riociguat (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- 10 Jan 2022 Results published in the Journal of Heart and Lung Transplantation
- 25 Apr 2020 Results (n=12) assessing clinical and echocardiographic effects of an upfront combination with riociguat and ambrisentan, presented at the 40th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.
- 25 Apr 2018 New trial record